A product indexed to an index of European biotech stocks

Publish-editorial — INSTRUMENTS PRESENTING A RISK OF CAPITAL LOSS DURING THEIR LIFE AND AT MATURITY

The performance of the product presented below is indexed to the price of an index. The funds raised during the marketing of the product presented below are therefore not directly intended for the financing of projects or companies linked to biotechnologies.

Only the index underlying the product is constructed in such a way as to select the shares of companies active in the biotechnology sector.

The funds invested in the products by the investor do not participate directly in the financing of the companies that make up the index.

The 100% UniCredit Certificate DE000HB2ZB12backed by the European Biotech index (DE000A2BL3K0) can be a way to position yourself on companies active in this field.

The European Biotech index thus traces the evolution of the share price of a maximum of 30 European companies active in the field of biotechnology, particularly in the pharmaceutical industry. At the time of inclusion of a company’s shares in the index, that company must have a market capitalization of at least €100 million and its shares must have a three-month daily trading volume of at least 300,000 euros on average.

Companies whose shares make up the index (as of 09.09.2022):

The composition of the index is adjusted semi-annually and weighted equally. In special cases, for example in the event of the takeover of one company by another, extraordinary adjustments may be made. The net distributions of the stocks included in the index are reinvested.

Defining biotechnologies

Biotechnology can be defined as the use of living organisms (bacteria, yeasts, cells, etc.) to produce goods such as food, medicine or industrial products. The field of application of biotechnology has widened thanks to technological and scientific progress resulting from several decades of research.

In 2020, according to research firm Global Markets insights (GMI), the market for biotech industries was valued at US$497 billion. GMI estimates that the market volume could reach around $950 billion by 2027.

Source: https://www.gminsights.com/industryanalysis/biotechnology-market

Warning

The public offering of these securities is made in accordance with the prospectus “DIP 2022 – Securities Note for Securities with Single-Underlying (without capital protection) I”, dated 18.05.2022, approved by the German Federal Financial Supervisory Authority (BaFin) and notified in France under the European passport to the Autorité des Marchés Financiers (AMF). This support is established by UniCredit Bank. This approval of the prospectus does not constitute a favorable opinion from the authorities on the securities offered. This information does not constitute investment advice, nor a proposal, request or recommendation to enter into a transaction.

100% CERTIFICATES ARE DIFFICULT TO UNDERSTAND SECURITIES AND ARE SOLELY INTENDED FOR EXPERIENCED INVESTORS WITH THE NECESSARY KNOWLEDGE AND EXPERIENCE TO ASSESS BENEFITS AND RISKS.

Investors are advised to read the prospectus carefully before making an investment decision in order to fully understand the potential risks and benefits associated with the decision to invest in the securities of UniCredit Bank AG and to refer to the section ” Risk Factors” of the prospectus available on the website www.bourse.unicredit.fr/documentation.

Due to their nature, these securities may involve liquidity risks which could result in a partial or total loss of the investment. This investment is also exposed to the credit risk of UniCredit Bank (S&P BBB+/ Moody’s A2/ Fitch BBB). The investor is also exposed to the risk of default, bankruptcy and resolution of UniCredit Bank. Potential investors must therefore ensure, before investing in the 100% Certificates, that they fully understand these instruments and the resulting risks.

More information on www.icf-markets.de and on https://www.bourse.unicredit.fr

Content provided by UniCredit – Exchange Products Team.